Florida biopharma Ligand Pharmaceuticals (Nasdaq: LGND) subsidiary Pelthos Therapeutics is to merge with Channel Therapeutics (NYSE American: CHRO), a developer of non-opioid pain treatments.
The merger will be supported by $50 million in capital raised from a group of strategic investors led by Murchinson.
This transaction presents a compelling opportunity to launch a commercial-ready product
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze